Article Details
Retrieved on: 2024-12-06 17:50:12
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Jefferies analyst Maury Raycroft initiated coverage of Mereo BioPharma (MREO) with a Buy rating and $7 price target The company's lead asset se...
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here